EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: incidence, pattern of failure, and clinical value of local consolidative therapy

Jinmeng Zhang, Jie Gao, Shanshan Jiang, Jiuang Mao, Li Chu, Xiao Chu, Xi Yang, Yida Li, Tiantian Guo, Yue Zhou, Dayu Xu, Jie Hu und 3 weitere

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03720-7 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Jinmeng Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Chinese Society of Clinical Oncology, the Shanghai Science and Technology Committee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the feasibility and potential clinical value of local consolidative therapy (LCT) in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer (NSCLC). Materials and methods PD-1/PD-L1 inhibitor-treated metastatic NSCLC patients with measurable disease in three academic centers were screened and those with adequate follow-up were included. Oligo-residual disease (ORD) was defined as residual tumors limited to three organs and five lesions evaluated at the best response among patients with partial response or stable disease after PD-1/PD-L1 inhibitors. Oligometastatic and multiple-metastatic disease (OMD/MMD) were similarly classified at baseline. Locoregional interventions, administered after effective treatment of PD-1/PD-L1 inhibitors and before initial disease progression, were defined as LCT. Patterns of initial progressive disease (PD) were classified as involving only residual sites (RP), only new sites (NP), or a combination of both (BP).

Results

Among the 698 patients included, ORD was documented in 73 (47.1%) of 155 patients with baseline OMD and 60 (11.0%) of 543 patients with baseline MMD. With a median follow-up of 31.0 (range, 6.0–53.0) months, 108 patients with ORD developed initial PD, with RP, NP, and BP occurring in 51 (47%), 23 (21.3%), and 34 (31.5%), respectively. Among the 133 patients with ORD, those receiving LCT ( n = 43) had longer progression-free survival (HR = 0.58, 95% CI 0.40–0.85, p = 0.01) and overall survival (HR = 0.49, 95% CI 0.30–0.79, p < 0.0001).

Conclusion

ORD occurs with a clinically relevant frequency among PD-1/PD-L1 inhibitor-treated metastatic NSCLC patients and LCT may provide extra survival benefits in those with ORD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedAgedAdultNeoplasm, ResidualB7-H1 AntigenAged, 80 and overProgrammed Cell Death 1 ReceptorIncidenceNeoplasm MetastasisFollow-Up StudiesRetrospective Studies

Stichwörter der Autor:innen

Local consolidative therapy (LCT)Non-small cell lung cancer (NSCLC)Oligo-residual disease (ORD)PD-1/PD-L1 inhibitorsRadiotherapy

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenProgrammed Cell Death 1 ReceptorCD274 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
  • Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China.
  • Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
  • Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Förderung

  • the Chinese Society of Clinical Oncology
  • the Shanghai Science and Technology Committee

Zitieren

APA

Zhang, J., Gao, J., Jiang, S., Mao, J., Chu, L., Chu, X., Yang, X., Li, Y., Guo, T., Zhou, Y., Xu, D., Hu, J., Chu, Q., Ni, J., & Zhu, Z. (2024). Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: incidence, pattern of failure, and clinical value of local consolidative therapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03720-7

Vancouver

Zhang J, Gao J, Jiang S, Mao J, Chu L, Chu X, et al. Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: incidence, pattern of failure, and clinical value of local consolidative therapy. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03720-7

BibTeX
@article{Zhang2024,
  author = {Zhang, Jinmeng and Gao, Jie and Jiang, Shanshan and Mao, Jiuang and Chu, Li and Chu, Xiao and Yang, Xi and Li, Yida and Guo, Tiantian and Zhou, Yue and Xu, Dayu and Hu, Jie and Chu, Qian and Ni, Jianjiao and Zhu, Zhengfei},
  title = {Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: incidence, pattern of failure, and clinical value of local consolidative therapy},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03720-7}
}
Kostenlos starten →